Seragon Biosciences administers SRN-901 orally to middle-aged mice, achieving a 34.4% extension of remaining lifespan and improved physical endurance. The compound integrates mTOR inhibition, autophagy activation, NAD+ enhancement, and senolytic stimulation to restore youthful gene expression and metabolic profiles, offering a promising approach to mitigate age-related decline and extend disease-free lifespan.
Key points
- Oral SRN-901 extends remaining lifespan by 34.4% and more than doubles endurance in middle-aged mice.
- Drug combines mTOR inhibition, autophagy activation, NAD+ enhancement, and senolytic stimulation to restore youthful gene expression.
- Multi-omics profiling and machine learning bioinformatics reveal pathway modulation, improved metabolic markers, and reduced senescence.
Why it matters: This study demonstrates a multi-targeted drug that robustly extends lifespan and healthspan, paving the way for next-generation longevity therapies.
Q&A
- What is mTOR?
- How does SRN-901 differ from rapamycin?
- What does healthspan mean?
- How does machine learning assist in this study?